To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects

NCT02823171 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Treatment A: 400 mg Pacritinib P3CT
DRUG: Treatment B: 400 mg of pacritinib FMI

Sponsor

CTI BioPharma

Collaborators

[object Object]